4-[(3-chloro-N-methylsulfonylanilino)methyl]-N-[(1R)-1,2,3,4-tetrahydronaphthalen-1-yl]benzamide
C25H25ClN2O3S — CID 99130942
Data last refreshed: (MolForge compound catalog, from PubChem)
About 4-[(3-chloro-N-methylsulfonylanilino)methyl]-N-[(1R)-1,2,3,4-tetrahydronaphthalen-1-yl]benzamide
4-[(3-chloro-N-methylsulfonylanilino)methyl]-N-[(1R)-1,2,3,4-tetrahydronaphthalen-1-yl]benzamide (PubChem CID 99130942) has the molecular formula C25H25ClN2O3S and a molecular weight of 469.01 g/mol. Its IUPAC name is 4-[(3-chloro-N-methylsulfonylanilino)methyl]-N-[(1R)-1,2,3,4-tetrahydronaphthalen-1-yl]benzamide.
Molecular Properties
| Compound Name | 4-[(3-chloro-N-methylsulfonylanilino)methyl]-N-[(1R)-1,2,3,4-tetrahydronaphthalen-1-yl]benzamide |
|---|---|
| PubChem CID | 99130942 |
| Molecular Formula | C25H25ClN2O3S |
| Molecular Weight | 469.01 g/mol |
| Exact Mass | 468.13 |
| IUPAC Name | 4-[(3-chloro-N-methylsulfonylanilino)methyl]-N-[(1R)-1,2,3,4-tetrahydronaphthalen-1-yl]benzamide |
| SMILES | CS(=O)(=O)N(Cc1ccc(C(=O)N[C@@H]2CCCc3ccccc32)cc1)c1cccc(Cl)c1 |
| InChI | InChI=1S/C25H25ClN2O3S/c1-32(30,31)28(22-9-5-8-21(26)16-22)17-18-12-14-20(15-13-18)25(29)27-24-11-4-7-19-6-2-3-10-23(19)24/h2-3,5-6,8-10,12-16,24H,4,7,11,17H2,1H3,(H,27,29)/t24-/m1/s1 |
| InChIKey | GYCQURFZYLZQHS-XMMPIXPASA-N |
| XLogP | 5.11 |
| TPSA | 66.48 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 3 |
| Rotatable Bonds | 6 |
| Heavy Atoms | 32 |
| Complexity | — |
Lipinski Rule of Five
1 violation
| Rule | Value |
|---|---|
| MW ≤ 500 | 469.01 |
| LogP ≤ 5 | 5.11 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 3 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 99130942 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.